Glenmark Pharmaceuticals

Over a thousand dermatologists and pharmaceutical partners gathered for the highly anticipated event of the year, the 47th Annual Philippine Dermatology Convention, held at the Marriott Hotel in Pasay City from November 5–8, 2024. This year, the Philippine Dermatological Society (PDS) placed a strong emphasis on “Global Synergy,” fostering connections with international partners in the field of dermatology. As a proud partner of the PDS, we at Glenmark actively participated with enthusiasm and pride, showcasing our commitment to the field. Dressed in our finest Filipiniana attire, we welcomed guests to our Bahay Kubo-themed booth, where we highlighted our trusted brands and introduced new launches, including Oflomil and Dipsotrex B. Our booth became a hub of interaction, not only for Philippine-based dermatologists but also for international delegates who appreciated the cultural experience and professional exchange. True to our renowned Filipino hospitality, we warmly greeted and accommodated our visitors with traditional treats, such as warm taho and refreshing ice cream, making their experience memorable. The three-day event was a resounding success for Glenmark Philippines Inc. We eagerly anticipate more opportunities to collaborate and innovate as we continue to help patients achieve healthy skin.

COPD: Need to Bridge Awareness Gaps in Care Chronic Obstructive Pulmonary Disease (COPD) remains one of the most significant healthcare challenges worldwide, impacting approximately 12% of the global population. In Europe and emerging markets, the burden of COPD is significant. Late diagnoses and limited access to optimal care often leave patients struggling with severe symptoms and complications, significantly affecting their quality of life. The economic impact is equally staggering. In the European Union alone, direct annual costs associated with COPD are estimated at €38.6 billion—a figure that emphasizes the need for urgent and sustained intervention. Beyond its respiratory challenges, COPD places individuals at heightened risk of cardiopulmonary complications, premature mortality, and comorbid conditions such as hypertension and diabetes, making comprehensive care a critical need. Early intervention is key to addressing this growing health crisis. Greater awareness of risk factors—such as smoking, environmental pollution, and occupational hazards—paired with regular health screenings, can significantly improve early detection and outcomes. However, awareness alone is not enough. Ensuring equitable access to innovative therapies and integrated care solutions is vital for empowering patients and improving their quality of life. This requires a collaborative approach, uniting healthcare professionals, policymakers, and industry leaders to prioritize holistic, patient-centered care. Together, we can create a healthcare ecosystem that supports early diagnosis, provides access to cutting-edge therapies, and offers long-term disease management. At Glenmark Pharmaceuticals, we are committed to transforming the lives of patients living with COPD. By introducing effective therapies and exploring novel treatment approaches, we aim to address the diverse needs of COPD patients. Our mission is to improve their quality of life and provide them with the care they deserve. Whether it’s through raising awareness, supporting patients, or advancing innovative solutions, we all have a role to play. Together, we can make a lasting impact on the lives of millions, ensuring a healthier future for those affected by COPD. #WorldCOPDDay #RespiratoryHealth #COPDAwareness #HealthcareInnovation #Pharmaceuticals #PublicHealth #PatientEmpowerment #LungHealth Glenmark Pharmaceuticals

Celebrating 47 years of innovation and growth. #ANewWayForANewWorld #GlenmarkPharma #Anniversary #47YearsOfGrowth #Innovation

Our Q2 FY 2025 results are out now! To know more about our quarterly performance, please visit: https://lnkd.in/dZMG5gVw #GlenmarkPharma #QuarterlyResults #Investors

In a recent interview with The Economic Times our CMD, Glenn Saldanha, shared insights into Glenmark’s transformation journey and renewed focus on branded pharmaceuticals. With a strong foundation and an aggressive growth strategy, we are poised to deliver greater value through our core therapeutic areas: Respiratory, Dermatology, and Oncology. #GlenmarkPharma #Leadership #ANewWayForANewWorld #TransformationJourney

Supporting Healthier Lung Through Smoking Cessation As a leader in respiratory health, Glenmark is deeply committed to addressing one of the most pressing public health challenges: smoking cessation. The statistics are alarming: smoking contributes to nearly 760,000 cancer cases annually in Europe alone, costing the economy 2.5% of GDP. The crisis extends beyond individual health, straining our healthcare systems and affecting the overall social and economic fabric of our communities. At Glenmark, we recognize that addressing this challenge is essential for empowering individuals to lead healthier, smoke-free lives. Our approach combines cutting-edge therapies with comprehensive support systems, ensuring that our solutions are not only innovative but also accessible. Smoking cessation is a cornerstone of our respiratory focus, and we are dedicated to making a tangible difference. The urgency of quitting is underscored by its rapid benefits—improved lung function, reduced disease risks, and enhanced quality of life. Our commitment is clear: a future where every individual can achieve a smoke-free life. Glenmark continues to lead the way in respiratory care, transforming the promise of a healthier tomorrow into a reality for all. Together, we can build a smoke-free future that enhances the well-being of individuals and communities alike. #Glenmark #RespiratoryCare #LungHealth #InnovationInHealthcare #HealthyLungs  #QuitSmoking 

To know more about this announcement, visit https://lnkd.in/dXTDH7vc

We are proud to announce our $1.3 million donation to South Piedmont Community College in support of their new Aseptic Training Facility in Monroe. This state-of-the-art facility will play a vital role in training the next generation of pharmaceutical professionals, providing hands-on training and certification in aseptic processing. This investment reflects our ongoing commitment to workforce development and building a stronger talent pipeline in the region. Together, we are empowering the workforce and shaping the future of the pharmaceutical industry. #Glenmark #GlenmarkPharma #ANewWayForANewWorld #Empowerment #Commitment Marc Kikuchi Jesse Ross Wilfredo Ortiz Karen Rocco Laura Lester Shweta Munjal

Psoriasis is more than a skin condition—it can impact joint health, daily routines, and overall well-being. At Glenmark, we are committed to advancing patient outcomes for those affected by this chronic condition. Through continuous research and patient-centered care, we aim to raise awareness and deepen understanding of the complexities of psoriasis, helping patients lead healthier, more fulfilling lives. #PsoriasisAwareness #SupportAndUnderstanding #GlenmarkCares #GlenmarkPharma

Important Notice We urge the public to be vigilant against fraudulent recruitment schemes claiming to represent Glenmark Pharmaceuticals. Please be aware that Glenmark does not charge any fees or ask for any valuables during any stage of the recruitment process. Stay informed and be more vigilant. #Glenmark #CautionNotice #FraudAlert #RecruitmentScam #StaySafe